Indication expansion to meet Longevity market demand

Several compounds have demonstrated life-extending effects in animal models, some of which are currently being tested for their ability to exert anti-aging effects in humans. Some humans are simply taking them anyway.

Aging is associated with numerous diseases and conditions, including cancer, Alzheimer’s disease, diabetes and cardiovascular disease. Therefore, interventions promoting Longevity are expected to prevent such age-related conditions.

Longevity.Technology: The results achieved from existing and approved drug compounds are exciting the market and starting to move into mainstream consciousness. Companies like Ponce De Leon Health favour using generally recognised as safe (GRAS). Either way, the market for companies looking to accelerate time-to-market for independently and clinically-validated Longevity therapies is hotting-up.

Several compounds have been reported to delay aging in animal models; among them, rapamycin and metformin are the most extensively studied. Rapamycin, a bacterial metabolite, was first shown to extend lifespan in fruit flies by promoting cell survival during stressful conditions and is the first drug reported to extend lifespan in mice [1].

Metformin, most commonly known for its use as the first-line treatment for type 2 diabetes, has been shown to regulate metabolic and cellular processes associated with the development of age-related conditions in animal models, in addition to its effects on glucose metabolism [2]. An early human study to assess the benefit of metformin in Longevity [3] is planned to expand (TAME) this year under Nir Barzilai.


“Some prominent scientists proclaim we are just 10 or 20 years away from widely available inexpensive drugs that will extend healthy life expectancy to 150”


 

According to the recent Longevity Trends 2020 report, “There is an emerging and increasingly serious field of drug development counteracting the aging process. Some prominent scientists proclaim we are just 10 or 20 years away from widely available inexpensive drugs that will extend healthy life expectancy to 150. Many have been taking metformin for years, and extol the human life-extending qualities of this drug, more usually used in the treatment of Type 2 Diabetes,” says Yvonne Sonsino, Partner of Multinational Client Group and Global Co-Leader of Mercer’s Next Stage [4].

GDF11 has recently emerged as a promising anti-aging agent. The naturally occurring molecule GDF11 is crucial for stem cell DNA repair. During aging, stem cells accumulate DNA damage, leading to stem cell senescence, the main characteristics of which is the decline in stem cell quantity and function [5]. Exogenous GDF11 can boost the regenerative potential of the body, and thereby reverse aging and improve the symptoms of age-related conditions. In an anecdotal human study, GDF11 supplements improved several aging biomarkers, and led to cardiac age reversal, increased skin elasticity, stamina, and mental clarity, as well as reduced average blood pressure, augmentation pressure and pulse rate [6].

“Not having IRB or FDA approval has not been much of an issue for us. People just want results and if you have a serious medical condition like BPH, plaque, heart failure or early dementia, GDF11 is the only regimen that can really turn things around,” says Steve Perry, the CEO of GDF11 Rejuvenation, Inc.

Questions exist regarding the efficacy of these drugs as anti-aging agents, owing to the lack of data from well-designed large-cohort controlled studies. Although certain compounds have emerged as potential anti-aging drugs based on studies in animal models, more systematic research is needed to prove their efficacy in humans.

[1] https://www.nature.com/articles/s41598-019-44106-5

[2] https://www.sciencedirect.com/science/article/abs/pii/S104327601930147X

[3] https://clinicaltrials.gov/ct2/show/study/NCT02432287

[4] https://bit.ly/381Rzfh

[5] https://bit.ly/3bmErDQ

[6] https://gdf11rejuvenation.com

 

 

Carla Heyworth
Carla is sub editor at Longevity.Technology and she's the glue that keeps the team on track and the articles rolling-out. She has an extensive background in B2B communications, events and marketing. Carla's a visual person and can often be found behind a camera or editing photos

Latest articles

Biomarkers for aging – a consensus is needed now more than ever

Slowing, stopping and even reversing aging – how can we research progress if we can't measure success? Biomarkers of aging are pretty important in the...

Hereafter: conversations in the afterlife

We speak to Dadbot creator James Vlahos about using conversational AI to better remember loved ones who have passed away; a very interesting step...

VR and AI used to generate structures to attack Coronavirus

Virtual reality and artificial intelligence come together to generate new chemicals from scratch which could be used against SARS-CoV-2. A new paper has outlined...

Exclusive video interview: Human Longevity Inc.’s Chairman

After $0.5bn cumulative investment, Human Longevity Inc. pivots into high-end medical services to seek scale and ROI. For a few years we tracked Human Longevity Inc.'s...